Kim In Cheol, Youn Jong Chan, Kobashigawa Jon A
Division of Cardiology, Keimyung University Dongsan Medical Center, Daegu, Korea.
Division of Cardiology, Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong, Korea.
Korean Circ J. 2018 Jul;48(7):565-590. doi: 10.4070/kcj.2018.0189.
Heart transplantation (HTx) has become standard treatment for selected patients with end-stage heart failure. Improvements in immunosuppressant, donor procurement, surgical techniques, and post-HTx care have resulted in a substantial decrease in acute allograft rejection, which had previously significantly limited survival of HTx recipients. However, limitations to long-term allograft survival exist, including rejection, infection, coronary allograft vasculopathy, and malignancy. Careful balance of immunosuppressive therapy and vigilant surveillance for complications can further improve long-term outcomes of HTx recipients.
心脏移植已成为特定终末期心力衰竭患者的标准治疗方法。免疫抑制剂、供体获取、手术技术及心脏移植术后护理等方面的改进,已使急性移植物排斥反应大幅减少,而此前急性移植物排斥反应曾显著限制心脏移植受者的存活。然而,长期移植物存活仍存在局限性,包括排斥反应、感染、冠状动脉移植物血管病变及恶性肿瘤。免疫抑制治疗的谨慎平衡及对并发症的密切监测可进一步改善心脏移植受者的长期预后。